A clinical oncology research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with ...

Medidata has supported the NCI Cancer Therapy Evaluation Program (CTEP) study portfolio with tools across the Medidata Platform for the past 17 years, strengthening the collaboration and reinforcing ...

With more than 15 years of experience in product delivery and portfolio management, Tendulkar has been working at Intelligent Medical Objects (IMO) Health for nearly four years. She shares her advice ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD(TM) CorEvitas(TM) Myasthenia Gravis (MG) Registry. This ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, and IgniteData, a leader in intelligent clinical trial data automation, today announced a new ...

Missing data in clinical trials remains an ongoing concern. With the expansion of data privacy efforts and the consequent inability to contact trial participants for follow-up, the magnitude and ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in ...

Lumenis Be. Ltd., a leading energy-based medical device company, unveiled the latest edition of its groundbreaking multi-application aesthetic platform, the Stellar M22™ with XPL™ Technology powered ...

Breast cancer is a highly heterogeneous malignancy among women worldwide. Traditional prognostic models relying solely on clinicopathological features offer limited predictive accuracy and lack ...

Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...